Literature DB >> 8682464

Endoscopic sphincterotomy prior to laparoscopic cholecystectomy for the treatment of cholelithiasis.

K K Chang1, L R Mo, M P Yau, R C Lin, J Y Kuo, C C Tsai.   

Abstract

BACKGROUND/AIMS: Laparoscopic cholecystectomy is the standard treatment for symptomatic cholecystolithiasis; however, there is debate on the management of patients with concomitant common bile duct stones. Several options have been suggested; endoscopic sphincterotomy and laparoscopic common bile duct exploration seemed to be the preferred methods at this moment.
MATERIALS AND METHODS: We performed endoscopic sphincterotomy prior to laparoscopic cholecystectomy in 51 cases of acute symptomatic cholelithiasis.
RESULTS: Endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy procedure-related complication rate was 5.4%, including 1 pancreatitis, 1 cholangitis, and 2 major bleeds. After follow up period of 15-42 months, recurrent stones were found in 2 patients.
CONCLUSION: Endoscopic sphincterotomy combined with laparoscopic cholecystectomy is a safe and effective therapy for symptomatic cholecystolithiasis with concomitant choledocholithiasis. Recurrent stones did occur, but further studies are needed to compare the incidence of recurrent stones after endoscopic sphincterotomy and after laparoscopic common bile duct exploration.

Entities:  

Mesh:

Year:  1996        PMID: 8682464

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Conversion rate of laparoscopic cholecystectomy after endoscopic retrograde cholangiography in the treatment of choledocholithiasis: does the time interval matter?

Authors:  A de Vries; S C Donkervoort; A A W van Geloven; E G J M Pierik
Journal:  Surg Endosc       Date:  2005-05-19       Impact factor: 4.584

2.  Identification of risk factors for an unfavorable laparoscopic cholecystectomy course after endoscopic retrograde cholangiography in the treatment of choledocholithiasis.

Authors:  S C Donkervoort; O van Ruler; L M Dijksman; A A van Geloven; E G Pierik
Journal:  Surg Endosc       Date:  2009-08-26       Impact factor: 4.584

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.